Medication info
Huresto 20 mg (Rosuvastatin Calcium)

Huresto 20 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hubist Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
PTP - 30 tablets/PTP [(15 tablets/PTP x 2)]
Approval status
Active

MFDS item code 201404930 · Approved 2014.10.27 · Insurance code 628800380

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Hubist Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • early family history of coronary heart disease
View approved original text

This medication is used as an adjunct when diet and exercise are not sufficient to control primary hypercholesterolemia and mixed dyslipidemia. It is also helpful as an adjunct to diet or other lipid-lowering therapies in patients with familial hypercholesterolemia. In particular, it lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. It is effective in pediatric patients with heterozygous familial hypercholesterolemia aged 10 to 17 years and is used to reduce total cholesterol, LDL-cholesterol, and Apo-B protein levels. It is also suitable as an adjunct to diet for patients with primary dysbetalipoproteinemia. Additionally, it helps reduce the risk of stroke, myocardial infarction, and vascular revascularization procedures in men over 50 and women over 60 with elevated high-sensitivity C-reactive protein levels. This medication is used to reduce the risk of cardiovascular diseases related to dyslipidemia and improve health.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This drug should not be administered to certain patients. For example, it is contraindicated in individuals with allergies to the components of this drug, those with liver function issues, muscle diseases, and patients with severely impaired kidney function. Women who are pregnant or breastfeeding, as well as women of childbearing potential who are not using appropriate contraception, should not take this medication. It should only be administered to women of childbearing age after explaining the low likelihood of pregnancy and fetal risks. Patients at high risk for muscle diseases, such as those with moderate to severe kidney impairment, hypothyroidism, a family history of muscle diseases, or alcoholics, should avoid high doses of this medication. This medication contains lactose and should not be administered to patients with lactose intolerance or certain genetic metabolic disorders. While taking this drug, patients with a history of excessive alcohol intake or liver disease need regular liver function tests. Patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome should first treat the underlying disease. Myalgia, myopathy, and rarely severe muscle breakdown (rhabdomyolysis) may occur; therefore, if muscle pain or weakness occurs, the physician must be notified immediately, and if necessary, blood tests should be conducted to check for muscle damage. This drug may interact with other medications; caution is especially advised when used in conjunction with fibrates, certain antibiotics, antifungals, and immunosuppressants. The combination with specific drugs may increase the blood concentration of this drug, thereby increasing the risk of side effects. Pregnant or breastfeeding women should not use this medication, and women who could become pregnant must use appropriate contraception. In case of overdose, there is no specific antidote, so symptomatic treatment and monitoring of liver function and muscle enzymes are necessary. This drug does not significantly affect the ability to drive or operate machinery, but caution should be exercised as dizziness may occur. Finally, this drug may rarely cause serious skin reactions, liver dysfunction, kidney problems, and other severe side effects, so if any unusual symptoms occur, consult healthcare personnel immediately.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container away from exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness and safety.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

PTP - 30 tablets/PTP [(15 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.